September 6, 2020

Verisk Analytics, Inc. (NASDAQ:VRSK) Receives Average Recommendation of “Hold” from Brokerages

Verisk Analytics, Inc. (NASDAQ:VRSK) Receives Average Recommendation of "Hold" from Brokerages


Verisk Analytics, Inc. (NASDAQ:VRSK) has been assigned an average rating of “Hold” from the seventeen ratings firms that are presently covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have given a buy rating to the company. The average 1-year price target among brokerages that have covered the stock in the last year is $172.64.

A number of analysts have recently issued reports on VRSK shares. Morgan Stanley raised their target price on shares of Verisk Analytics from $191.00 to $200.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. BidaskClub cut shares of Verisk Analytics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, August 25th. Barclays raised their target price on shares of Verisk Analytics from $165.00 to $210.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Finally, BMO Capital Markets raised their target price on shares of Verisk Analytics from $156.00 to $181.00 and gave the stock a “market perform” rating in a research note on Thursday, August 6th.

Shares of VRSK traded down $4.51 during midday trading on Friday, reaching $182.77. The stock had a trading volume of 697,767 shares, compared to its average volume of 661,184. The firm has a 50 day simple moving average of $185.98 and a 200-day simple moving average of $164.62. Verisk Analytics has a one year low of $116.61 and a one year high of $193.61. The firm has a market cap of $29.68 billion, a PE ratio of 58.58, a P/E/G ratio of 3.58 and a beta of 0.67. The company has a current ratio of 0.59, a quick ratio of 0.59 and a debt-to-equity ratio of 1.24.

(Ad)

The coronavirus knocked the wind out of stocks. But there are 5 Companies that could be HUGE in 2020 and 2021! Time to get your FREE Report on these 5 Companies that could DOMINATE! (Tickers Included)

Verisk Analytics (NASDAQ:VRSK) last announced its quarterly earnings data on Tuesday, August 4th. The business services provider reported $1.29 EPS for the quarter, beating analysts’ consensus estimates of $1.19 by $0.10. The company had revenue of $678.80 million during the quarter, compared to the consensus estimate of $685.84 million. Verisk Analytics had a net margin of 19.12% and a return on equity of 36.42%. The company’s quarterly revenue was up 4.0% on a year-over-year basis. During the same quarter last year, the firm posted $1.10 EPS. As a group, research analysts forecast that Verisk Analytics will post 4.89 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Tuesday, September 15th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a dividend yield of 0.59%. The ex-dividend date is Monday, September 14th. Verisk Analytics’s payout ratio is presently 24.66%.

In other news, CEO Scott G. Stephenson sold 98,513 shares of the business’s stock in a transaction that occurred on Monday, August 31st. The shares were sold at an average price of $186.23, for a total value of $18,346,075.99. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Mark V. Anquillare sold 27,433 shares of the business’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $186.47, for a total transaction of $5,115,431.51. Following the completion of the transaction, the chief operating officer now owns 88,935 shares of the company’s stock, valued at $16,583,709.45. The disclosure for this sale can be found here. Insiders sold a total of 190,354 shares of company stock valued at $35,883,234 over the last 90 days. Corporate insiders own 2.55% of the company’s stock.

Large investors have recently modified their holdings of the company. Public Employees Retirement Association of Colorado grew its holdings in shares of Verisk Analytics by 2,693.4% during the 1st quarter. Public Employees Retirement Association of Colorado now owns 599,384 shares of the business services provider’s stock valued at $83,542,000 after purchasing an additional 577,927 shares during the last quarter. Stratos Wealth Partners LTD. bought a new stake in shares of Verisk Analytics during the 1st quarter valued at approximately $441,000. Forsta AP Fonden bought a new stake in shares of Verisk Analytics during the 1st quarter valued at approximately $3,331,000. KBC Group NV grew its holdings in shares of Verisk Analytics by 25.9% during the 1st quarter. KBC Group NV now owns 21,151 shares of the business services provider’s stock valued at $2,948,000 after purchasing an additional 4,349 shares during the last quarter. Finally, GWM Advisors LLC grew its holdings in shares of Verisk Analytics by 35.5% during the 1st quarter. GWM Advisors LLC now owns 6,329 shares of the business services provider’s stock valued at $882,000 after purchasing an additional 1,658 shares during the last quarter. Institutional investors own 88.17% of the company’s stock.

Verisk Analytics Company Profile

Verisk Analytics, Inc provides data analytics solutions in the United States and internationally. It provides predictive analytics and decision support solutions to customers in rating, underwriting, claims, catastrophe and weather risk, natural resources intelligence, economic forecasting, and various other fields.

Further Reading: Understanding dividend yield and dividend payout ratio

Verisk Analytics, Inc. (NASDAQ:VRSK) Receives Average Recommendation of "Hold" from Brokerages

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]

8 Pharmaceutical Companies Working on a Coronavirus Cure

We are living through interesting times. Not an hour goes by when Americans don’t receive some reminder of the impact the coronavirus has on our lives. The race is on for an effective, FDA-approved treatment for the virus. Despite, vaccines being available for human trial in record time, we are many months away from having a viable vaccine.

However, we may be somewhat closer in finding some antiviral treatments. And if you’ve watched the market closely this week, any news on that front tends to move the market in a positive direction.

That brings up another truth of investing. There are some stocks that thrive from other stocks misery. And that’s why we’ve put together this special report. If you’re an investor who is looking to jump into this bear market, the pharmaceutical sector is a logical choice.

A combination of big-name drug companies as well as smaller startup companies are working around the clock to develop vaccines or treatments that will target the infection caused by the novel coronavirus.

View the “8 Pharmaceutical Companies Working on a Coronavirus Cure”.



Click Here to Read Original Story

Leave a Reply

Your email address will not be published. Required fields are marked *